Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 9/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13084382 | 0.89 | ADORA3 (0.49) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL14030781 | 0.88 | ADORA3 (0.49) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL13084383 | 0.86 | ADORA3 (0.46) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL13084354 | 0.81 | ADORA3 (0.44) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL13084343 | 0.81 | ADORA3 (0.46) | ADORA3ADORA2AADORA1 | |
| SCHEMBL13084342 | 0.81 | LMNA (0.47) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL14030794 | 0.77 | EHMT1 (0.43) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL13046064 | 0.74 | DNMT1 (0.49) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL14003428 | 0.72 | CYP2C19 (0.43) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL14003429 | 0.71 | HINT1 (0.57) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807685-B2 | Therapeutic compounds | CBT DEVELOPMENT LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-20080076776-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076776-A1 | Therapeutic compounds | FPR3, OGFR, OPRK1 | ADORA3 370/4885SLC29A1 3642/4885ADORA2A 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.